Intro

Nepsone is a preclinical-stage pharmaceutical company developing drugs to treat dermatological conditions that arise due to an imbalance in the autonomic nervous system.

Currently, these conditions are believed to originate in the immune system. Nepsone foundational neuroimmunology theory on the origin of psoriasis teaches us that an imbalance in neuropeptide activity in the body leads to these conditions.

Our drugs are designed to utilize the body’s natural mechanisms to bring back balance and alleviate the disease.

Technology Development Fund (Rannís)

Nepsone ehf has been awarded a grant from Tækniþróunarsjóður (Technology Development Fund) of Rannís (The Icelandic Centre for Research).

Technology Development Fund The Icelandic Center for Research

The People of Nepsone

Stefan Jokull Sveinsson

Stefan Jokull Sveinsson

CEO, M.Sc

Svandis Kristjansdottir

Svandis Kristjansdottir

Head of R&D Quality, M.Sc

Morten Fjordholt

Morten Fjordholt

CDO, M.Sc

Sigurður Berntsson

Sigurdur Berntsson

CFO, Cand. Oecon

Gunhild L Skovgaard

Gunhild L Skovgaard

Head of Clinical R&D, MD

Jón Pétur Jóelsson

Jon Petur Joelsson

Head of R&D, PhD

Hakon Hrafn Sigurdsson

Hakon Hrafn Sigurdsson

R&D Consultant, PhD

Tomas Thorvaldsson

Tomas Thorvaldsson

Chairman of the Board

Birkir Sveinsson

Birkir Sveinsson

Founder / Member of the Board

Ragnar Bjarnason

Ragnar Bjarnason

Member of the Board

Gísli E. Haraldsson MD

Gisli E. Haraldsson MD

Member of the Board

Contact Us

Nepsone ehf.
Fiskislod 37b
101 Reykjavik
Iceland

info@nepsone.com

+354 555 1634, +354 840 3332